The primary therapeutic benefit of Sancuso is to provide prophylactic prevention of the highly distressing symptoms of nausea and vomiting, specifically in adults undergoing chemotherapy treatment. This medication is commonly used in situations where patients experience these symptoms associated with moderately and/or highly emetogenic chemotherapy regimens. Its use may assist with managing symptom burden and contributes to improving comfort during periods of heightened symptoms.

The medication is used for symptomatic management in the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

---

Prophylactic Support for Chemotherapy-Induced Nausea and Vomiting (CINV)

This medication is commonly applied in the context of systemic cancer therapy to support the prevention of the emetic response and the associated sensation of sickness. It is used across conditions where patients are receiving chemotherapy with a high potential to cause symptoms that create noticeable physiological strain. This medication is applied to provide supportive symptomatic relief that helps ease the overall burden of symptoms.

Sustained Relief for Multi-Day Symptom Patterns

Sancuso is generally used in clinical settings that involve recurrent or episodic manifestations, such as during prolonged or multiple-day chemotherapy regimens. It is relevant for managing symptom clusters that may appear suddenly or intensify over time, providing supportive relief against both acute and delayed symptoms. This assists with supporting functional stability and contributes to improved comfort throughout the symptomatic phases.

Quick Fact: Relief for Treatment-Related Sickness This medication is considered relevant for managing symptoms that interfere with daily comfort and is commonly used across conditions presenting with acute, recurrent, and episodic emetic manifestations.

Official Eligibility and Restrictions

Sancuso is approved for use in adults who are receiving moderately or highly emetogenic chemotherapy regimens. Regulatory documentation defines precise exclusions and limitations for other patient groups.

Eligibility Status	Population/Condition
Contraindicated	Patients with known hypersensitivity to the active substance, granisetron, or to any component of the transdermal system. Use is also contraindicated in patients allergic to other 5-HT3 receptor antagonists (EU/UK labeling).
Use Not Established	Pediatric patients (children and adolescents under 18 years) due to insufficient data on safety and effectiveness.

Special Population Cautions

Use requires special caution in individuals with pre-existing cardiac rhythm disorders and those with risk factors for gastrointestinal obstruction or a history of recent abdominal surgery. While no dose adjustment is required for renal or hepatic impairment, regulatory labels advise that caution must be exercised in these patients. For pregnancy, use is conditional and generally advised against unless clearly needed, and breastfeeding should be discontinued during treatment.

The official regulatory profile for Sancuso (granisetron transdermal system) defines interactions based on pharmacodynamic effects, metabolic clearance, and administration conditions.

Interactions are documented with specific medicine categories. Co-administration with serotonergic drugs, including SSRIs and SNRIs, is associated with the risk of developing Serotonin syndrome. Additionally, the concurrent use of 5-HT3 receptor antagonists has been reported to cause a block in the analgesic effect when administered with oral paracetamol.

The clearance of granisetron is primarily mediated by the hepatic enzymes CYP1A1 and CYP3A4. Consequently, substances classified as inducers or inhibitors of these enzymes, such as Phenobarbital, may change the clearance and half-life of granisetron.

Two critical administration constraints are noted in the official labeling. The transdermal system must not be used concomitantly with other forms of granisetron (e.g., oral or injection) to prevent excessive exposure. Furthermore, the product label mandates a strict administration restriction against applying any source of external heat (e.g., heating pads or heat lamps) over or near the patch. This restriction is necessary because prolonged heat exposure causes an increase in the plasma concentrations of the drug. These restrictions structure the official parameters for use.

The mechanism of Granisetron centers on its function as a selective antagonist of the 5- HT3 receptor. This receptor is a specialized ligand-gated ion channel that is normally activated by the neurotransmitter Serotonin (5- HT). By binding to the receptor, the molecule competitively blocks the action of 5- HT, thereby inhibiting the influx of cations ( Na^+, Ca^2+) necessary to trigger a nerve impulse. This action is the molecular foundation for interrupting the serotonergic signal cascade.

Granisetron exerts a dual-system blockade by acting both peripherally on the vagal nerve terminals in the gastrointestinal tract and centrally within the Chemoreceptor Trigger Zone (CTZ) and Nucleus Tractus Solitarius (NTS) of the brainstem. This dual interference prevents the afferent signals from the gut and the central triggers from reaching the Vomiting Center in the medulla. The resulting physiological effect is the inhibition of the final stage of the emetic reflex arc. The action profile is specific to serotonergic signaling, establishing the functional boundaries of the physiological effect.

Sancuso (granisetron transdermal system) is a patch applied to the skin for the prevention of chemotherapy-induced nausea and vomiting in adults receiving moderately or highly emetogenic chemotherapy regimens of up to five consecutive days.

Application and Timing

• When to Apply: A single patch must be applied to the skin a minimum of 24 hours before the start of chemotherapy, and can be applied up to a maximum of 48 hours prior.
• Application Site: The patch is applied to clean, dry, intact, and healthy skin on the upper outer arm. The transdermal system should not be placed on skin that is red, irritated, or damaged, and should not be cut. Only one patch should be worn at any time.
• Duration of Wear: The patch should remain in place for at least 24 hours after the completion of chemotherapy. The maximum wear time for the patch is 7 days, depending on the duration of the chemotherapy regimen.

Important Considerations

Action	Instruction
Sunlight/Heat	Avoid exposing the patch site to direct natural or artificial sunlight, including sunlamps or tanning beds, while wearing the patch and for 10 days after removal. The area should be covered with clothing. Do not apply external heat sources, such as heating pads or heat lamps, over or near the patch, as this may increase drug exposure.
Patch Removal	Peel the patch off gently. After removal, fold the patch in half so the sticky sides are together and dispose of it safely, out of the reach of children and pets.
Skin Reactions	If a severe or generalized skin reaction (such as an allergic rash) occurs, the patch must be removed, and a healthcare professional should be contacted.

Research Evidence / Overview of Studies for Sancuso

Evidence for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV)

The primary research for the Sancuso transdermal patch was evaluated for its use in the prophylaxis of nausea and vomiting associated with chemotherapy that carries a moderate or high potential to cause these symptoms. The main research design was a large Phase III Randomized, Double-Blind Trial that studied adult patients receiving chemotherapy over multiple consecutive days. These trials research examined measurements related to physical discomfort and systemic imbalance.

In these studies, researchers monitored the patients closely to measure the achievement of Complete Control (CC). This metric reflects specific criteria, including the absence of vomiting and retching, experiencing only mild or no nausea, and avoiding the need for rescue antiemetic medications throughout the observation period. The core evidence comes from comparisons against the established oral formulation of the active ingredient, as the pivotal trials did not use a placebo comparator.

Focus on Acute and Delayed Symptom Control

Research explored changes related to both the immediate period (the first day of chemotherapy) and the subsequent days. Research examined measurements reflecting daily functioning and overall patient-reported perceived discomfort across the entire course of treatment. Data show patterns related to the concentration profiles compared to the oral form. Research describes patterns related to how patients reported their experience for conditions characterized by cycles of stability and flare-ups.

Follow-up Duration and Pharmacokinetic Research

The main clinical trials monitored patients over defined follow-up durations, typically measuring the primary outcome from the start of chemotherapy until 24 hours after its final dose, often covering a total patch wear time of up to seven days. These studies contribute to the broader evidence landscape, but follow-up durations were limited and did not address long-term outcomes.

Key Evidence Gaps and Areas of Uncertainty

One key limitation is that the pivotal studies were designed to demonstrate non-inferiority, meaning the goal was evaluated to show the patch was not substantially worse than the existing oral medication, rather than exploring whether it was superior. Research on the use of the patch within multi-drug antiemetic regimens was not a focus of the pivotal trials. Furthermore, the safety and clinical use of the patch was not established in the pediatric population (children and adolescents).

Common questions about Sancuso (FAQ)

Q: What is the main difference between Sancuso and pills taken for nausea?

A: Sancuso is a transdermal patch that is applied to the skin and is designed to release the medicine continuously over a period of up to 7 days. According to regulatory documents, the oral formulation (pills) provides a different drug concentration profile, typically resulting in peaks and troughs of medicine in the bloodstream, and is generally taken only on the day of chemotherapy.

Q: Can the Sancuso patch be cut into a smaller piece?

A: No. The official product instructions indicate that the transdermal system is not designed to be cut into pieces. It is intended to be applied whole to ensure the intended dose is delivered safely and consistently.

Q: Can Sancuso cause problems with sleeping?

A: Yes, some issues related to sleep have been reported. Clinical studies and regulatory information indicate that side effects may include insomnia (difficulty sleeping) and somnolence (unusual drowsiness or sleepiness). Changes in sleep patterns are important information to communicate to the prescribing healthcare professional.

Q: Can Sancuso make me feel constipated?

A: Yes, constipation is officially listed as the most commonly reported side effect in clinical trials, occurring in 5% or more of patients using the patch. Constipation is a common side effect reported in clinical trials.

Q: Does Sancuso have any interactions with common pain relievers like ibuprofen?

A: Official labeling does not report any clinically relevant drug interactions specifically with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, it is important to communicate all pain relievers being used to the prescribing healthcare professional, especially as the drug class has been associated with interactions with other drugs like oral paracetamol (acetaminophen).

Q: Will Sancuso interact with my blood pressure medication?

A: Regulatory information indicates that rare adverse effects associated with the active ingredient include changes in blood pressure, such as temporary hypertension (high blood pressure) or hypotension (low blood pressure). For safety, the prescribing professional should be aware of all blood pressure medications being used.

Q: Is Sancuso safe for use in children undergoing chemo?

A: Sancuso is indicated for use in adults receiving chemotherapy. Official product information states that the safety and effectiveness of the patch have not been established in pediatric patients (children and adolescents).

Q: Does Sancuso work for all kinds of nausea, or just chemo-related sickness?

A: Sancuso has a specific regulatory indication. It is authorized only for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy regimens. Its use for other types of nausea has not been studied or approved.

Q: Do people develop tolerance to Sancuso over time?

A: Studies on the Sancuso patch focused on defined treatment periods, typically covering a single course of chemotherapy. Official regulatory documents do not address whether patients develop drug tolerance to the patch's effects over repeated, long-term use.

Q: Can Sancuso cause a headache?

A: Yes. According to official adverse event reports, headache is listed as one of the commonly reported side effects associated with transdermal granisetron.

Q: Is Sancuso used for morning sickness during pregnancy?

A: The regulatory indication for Sancuso is chemotherapy-induced nausea and vomiting (CINV). Official product information states that the use of Sancuso during pregnancy and lactation is generally not recommended.

Q: How should unused Sancuso patches be stored?

A: Regulatory documents state that unused Sancuso patches are to be stored in their original sealed packaging. Official storage instructions advise keeping them at room temperature (between 68°F and 77°F, or 20°C to 25°C) and out of the reach of children and pets.

Q: What is the risk of having an allergic reaction to the Sancuso patch?

A: Sancuso is contraindicated (should not be used) in anyone with a known hypersensitivity or severe allergy to granisetron or any component of the patch. Hypersensitivity reactions, including severe ones like anaphylaxis, have been reported with this class of anti-nausea drugs.

Q: Can I exercise or go swimming with the Sancuso patch on?

A: Official instructions permit normal activities like showering or washing. However, activities such as using a sauna, going swimming, or engaging in strenuous exercise are specified to be avoided because they can cause excessive heat or make the patch wet for a prolonged time.

Q: Does Sancuso make you tired or drowsy?

A: Official reports indicate that somnolence (unusual sleepiness or drowsiness) is listed as an uncommon adverse reaction associated with the patch. This potential effect should be monitored while the medicine is being used.

Q: Is Sancuso safe to use if I am also taking antidepressants?

A: Special precautions are noted when Sancuso is used with certain types of antidepressants called SSRIs and SNRIs (serotonergic drugs). Using Sancuso with these medicines may increase the risk of a serious condition called Serotonin Syndrome.

Q: Why do some people need to use Sancuso and others don't?

A: Sancuso is used based on the type of cancer treatment a person is receiving. It is specifically indicated for adults receiving chemotherapy regimens that carry a moderate or high risk of causing severe nausea and vomiting.

Q: Is it normal for the patch area to be slightly itchy?

A: Yes. Application site reactions, including localized pruritus (itching) and erythema (redness) at the patch site, are commonly reported. These reactions are generally mild in intensity.

Q: Will Sancuso interact with any herbal supplements or vitamins?

A: Official patient information indicates that the healthcare provider should be informed about all prescription and over-the-counter medicines, vitamins, minerals, herbal products, and other supplements being used.

Q: Can Sancuso be used for nausea from radiation therapy?

A: No. The regulatory indication for Sancuso is strictly for the prevention of nausea and vomiting caused by chemotherapy. Its use for nausea associated with radiation therapy is not included in the official labeling.

Q: Does Sancuso make you sensitive to the sun?

A: The area where the patch is applied must be protected from sunlight. Official warnings advise avoiding exposure of the patch site to direct natural or artificial sunlight, including sunlamps, by covering the area with clothing during wear and for 10 days after removal.

Q: Can the Sancuso patch be applied to a hairy part of the arm?

A: The patch application site must be clean, dry, intact, and healthy skin on the upper outer arm. For proper adherence and drug delivery, regulatory instructions typically emphasize applying the patch to an area with minimal or no hair.

Q: Are there any long-term side effects associated with using Sancuso multiple times?

A: Pivotal clinical studies for Sancuso were designed to evaluate its use over defined treatment periods, typically up to 7 days, to show its effect during a course of chemotherapy. Official regulatory documents indicate that these studies did not address the long-term outcomes of repeated or chronic use.

Q: How quickly does the drug wash out of my system after removing the patch?

A: The drug is primarily cleared from the body by liver enzymes. After the patch is removed, the remaining medication in the skin gradually absorbs. The full washout time is related to the drug's half-life, which is not provided in simple patient-facing instructions.

Q: What happens if I forget to take the Sancuso patch off after 7 days?

A: The official instructions specify the maximum wear time for the patch is 7 days. Because the patch is designed to deliver medicine over this period, keeping it on longer than 7 days may lead to a risk of excessive drug exposure.

Q: Does Sancuso help with vomiting as well as nausea?

A: Yes. Sancuso is officially indicated for the prevention of both nausea and vomiting caused by chemotherapy treatments.

Q: What kind of monitoring is typically done when a person is on Sancuso?

A: Patients should be monitored, particularly when taking other serotonergic drugs, to watch for symptoms of Serotonin Syndrome. The medicine can also potentially mask symptoms of progressive ileus (a type of intestinal blockage), requiring attention to changes in bowel activity.

Storing and Disposing of SANCUSO (Granisetron Transdermal System)

The SANCUSO transdermal patch must be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions. The product must not be frozen.

Storage Conditions

The patch must remain sealed in its individual sachet and stored within the original carton to ensure protection from light and moisture until the moment of application. All patches, both unused and used, must be kept out of the sight and reach of children.

Disposal Requirements

Used patches must be disposed of carefully because they still contain active medication. Upon removal, the patch must be folded firmly in half so the adhesive sides stick together. The folded patch should then be discarded immediately into the household trash.